Mannitol Dosage for Brain Bleed (Intracranial Hemorrhage)
For treating intracranial hemorrhage with elevated intracranial pressure or signs of brain herniation, administer 20% mannitol at a dose of 250 mOsm (approximately 0.25-1 g/kg) infused over 15-20 minutes, with larger doses of 0.5 g/kg over 15 minutes appropriate for acute intracranial hypertensive crisis. 1
Dosing Algorithm
Standard Dosing
- Adults: 0.25-1 g/kg of 20% mannitol over 15-20 minutes 1
- Acute crisis: 0.5 g/kg over 15 minutes for threatened herniation 1
- Pediatric patients: 0.25-1 g/kg over 20-30 minutes 2
Converting to 25% Mannitol
Since the question specifically asks about 25% mannitol, and guidelines recommend 20% mannitol at 250 mOsm:
- For 25% solution: Use 0.25-2 g/kg over 30-60 minutes 3
- Standard adult dose: 0.25-1 g/kg (equivalent to approximately 100-400 mL of 25% solution for a 70 kg patient)
- Acute crisis: Up to 2 g/kg may be used 3
Critical Implementation Points
Indications for Use
Mannitol should be administered for:
- Threatened intracranial hypertension with documented elevated ICP
- Signs of brain herniation (mydriasis, anisocoria, neurological deterioration) 1
- After controlling secondary brain insults (hypoxia, hypotension) 1
Timing and Frequency
- Maximum effect: Occurs at 10-15 minutes post-infusion 1
- Duration of action: 2-4 hours 1
- Repeat dosing: Can be given every 4-6 hours based on ICP monitoring 4
- Optimal frequency: Evidence suggests every 4 hours provides best ICP reduction in first 4 days 4
Essential Monitoring Requirements
- Place urinary catheter before administration 2
- Monitor serum osmolality: Keep <320 mOsm/kg 3
- Monitor sodium: Keep <160 mmol/L 3
- Administer through filter: Do not use solutions containing crystals 2
- Volume replacement: Required due to osmotic diuresis 1
Important Caveats and Contraindications
Absolute Contraindications
- Active intracranial bleeding (except during craniotomy) 3
- Severe dehydration 3
- Well-established anuria from severe renal disease 3
- Severe pulmonary congestion or frank pulmonary edema 3
Evidence-Based Concerns
Prophylactic use is NOT recommended: A 2026 study found that prolonged prophylactic mannitol administration was associated with increased perihemorrhagic edema growth and potentially worse outcomes 5. This represents the most recent high-quality evidence contradicting routine prophylactic use.
Dose-response relationship: The effect of mannitol on ICP is dose-dependent during the reduction phase, with ICP decreasing approximately 0.64 mmHg for each 1 mmHg of baseline ICP elevation 6. However, once ICP reaches a stable level, additional mannitol provides no further benefit (termed "mannitol saturation dosage") 7.
Duration limitations: Mannitol should not be used for more than 8 days 4. After 4-5 days, transition to as-needed dosing based on ICP monitoring rather than scheduled administration 4.
Comparison with Hypertonic Saline
At equiosmotic doses (250 mOsm), mannitol and hypertonic saline have comparable efficacy 1. However, mannitol uniquely improves cerebral oxygenation compared to other ICP-lowering therapies 1. The choice depends on side effect profile: mannitol causes osmotic diuresis requiring volume replacement, while hypertonic saline risks hypernatremia and hyperchloremia 1.
Clinical Outcomes Evidence
A 2005 randomized controlled trial found that low-dose mannitol (100 mL of 20% every 4 hours for 5 days) did not reduce 1-month mortality or improve 3-month functional outcomes in ICH patients 8. However, this study used lower doses than currently recommended guidelines. A 2007 trial showed only transient clinical improvement (30-60 minutes) without sustained benefit 9. These findings emphasize that mannitol should be reserved for documented elevated ICP or herniation signs, not used prophylactically or at subtherapeutic doses.